Baris Gencer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6680615/publications.pdf

Version: 2024-02-01

89 papers	3,273 citations	201674 27 h-index	161849 54 g-index
89 all docs	89 docs citations	89 times ranked	4609 citing authors

#	Article	IF	Citations
1	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. Nicotine and Tobacco Research, 2023, 25, 58-65.	2.6	2
2	PCSK9 Inhibition could be Effective for Acute Myocardial Infarction. Current Medicinal Chemistry, 2022, 29, 1016-1026.	2.4	3
3	European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology. European Journal of Preventive Cardiology, 2022, 29, 1060-1071.	1.8	25
4	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. European Journal of Preventive Cardiology, 2022, 29, 895-902.	1.8	18
5	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. American Heart Journal, 2022, 247, 24-32.	2.7	6
6	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
7	2021 European guidelines on cardiovascular prevention: Challenges for an evidenceâ€based patient care. European Journal of Clinical Investigation, 2022, 52, e13752.	3.4	0
8	Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). American Heart Journal, 2022, 251, 61-69.	2.7	40
9	Prognostic value of total testosterone levels in patients with acute coronary syndromes. European Journal of Preventive Cardiology, 2021, 28, 235-242.	1.8	7
10	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. European Journal of Preventive Cardiology, 2021, 28, 59-65.	1.8	30
11	The Reply. American Journal of Medicine, 2021, 134, e71.	1.5	0
12	Cardiovascular risk and testosterone â€“ from subclinical atherosclerosis to lipoprotein function to heart failure. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 257-274.	5.7	26
13	Air pollution triggers inflammation and cardiovascular events: now is the time to act. European Heart Journal, 2021, 42, 773-775.	2.2	9
14	Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2021, 325, 1061.	7.4	73
15	Improving 1-year mortality prediction in ACS patients using machine learning. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 855-865.	1.0	9
16	CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. Atherosclerosis, 2021, 335, 77-83.	0.8	6
17	Effect of Long-Term Marine É-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation, 2021, 144, 1981-1990.	1.6	59
18	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. Preventive Medicine Reports, 2021, 24, 101583.	1.8	0

#	Article	IF	Citations
19	Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism. Frontiers in Endocrinology, 2021, 12, 795492.	3.5	8
20	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 589-598.	1.0	7
21	Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. Drugs, 2020, 80, 229-239.	10.9	21
22	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International Journal of Cardiology, 2020, 299, 289-295.	1.7	1
23	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. International Journal of Cardiology, 2020, 303, 8-13.	1.7	5
24	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2020, 13, 618-628.	2.4	8
25	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2020, 396, 1637-1643.	13.7	167
26	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. JACC: CardioOncology, 2020, 2, 385-396.	4.0	7
27	Dynamical System Modeling of Self-Regulated Systems Undergoing Multiple Excitations: First Order Differential Equation Approach. Multivariate Behavioral Research, 2020, 56, 1-20.	3.1	5
28	Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology, 2020, 75, 2283-2293.	2.8	62
29	The Impact of Levothyroxine on Cardiac Function in Older Adults With Mild Subclinical Hypothyroidism: A Randomized Clinical Trial. American Journal of Medicine, 2020, 133, 848-856.e5.	1.5	31
30	Optimal Timing of Invasive Coronary Angiography following NSTEMI. Journal of Interventional Cardiology, 2020, 2020, 1-9.	1.2	6
31	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 2020, 141, 1600-1607.	1.6	61
32	Management of <scp>LDL</scp>â€cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. Clinical Cardiology, 2020, 43, 684-690.	1.8	7
33	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952.	6.1	56
34	Emerging Concepts and Applied Machine Learning Research in Patients with Drug-Induced Repolarization Disorders. Studies in Health Technology and Informatics, 2020, 270, 198-202.	0.3	1
35	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. Journal of Clinical Medicine, 2019, 8, 1002.	2.4	11
36	Gender Specificity and Interpretation of Functional Cardiac Imaging: Let's Talk about Sex. Thrombosis and Haemostasis, 2019, 119, 1379-1381.	3.4	2

#	Article	IF	Citations
37	Evolocumab for Early Reduction of LDLÂCholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). Journal of the American College of Cardiology, 2019, 74, 2452-2462.	2.8	135
38	Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naÃ¯ve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis, 2019, 284, 253-259.	0.8	9
39	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. PLoS ONE, 2019, 14, e0211464.	2.5	6
40	Inflammation during acute coronary syndromes â€" Risk of cardiovascular events and bleeding. International Journal of Cardiology, 2019, 287, 13-18.	1.7	22
41	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2019, 49, e13117.	3.4	24
42	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. Journal of Clinical Medicine, 2019, 8, 2035.	2.4	10
43	Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study. Swiss Medical Weekly, 2019, 149, w20049.	1.6	1
44	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	11
45	So lowâ€¦ so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors. European Heart Journal, 2018, 39, 382-384.	2.2	4
46	Adverse effects of statin therapy: perception vs. the evidence â€" focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	2.2	262
47	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 129-138.	1.0	70
48	Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. European Heart Journal, 2018, 39, 503-507.	2.2	106
49	Design of the randomized, placeboâ€controlled evolocumab for early reduction of LDLâ€cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clinical Cardiology, 2018, 41, 1513-1520.	1.8	20
50	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. PLoS ONE, 2018, 13, e0195174.	2.5	21
51	Lipid management in ACS: Should we go lower faster?. Atherosclerosis, 2018, 275, 368-375.	0.8	27
52	Impact of Thyroid Hormone Therapy on Atherosclerosis in the Elderly With Subclinical Hypothyroidism: A Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2988-2997.	3.6	34
53	Lipoprotein(a): the perpetual supporting actor. European Heart Journal, 2018, 39, 2597-2599.	2.2	11
54	Prognostic value of pulse pressure after an acute coronary syndrome. Atherosclerosis, 2018, 277, 219-226.	0.8	15

#	Article	IF	Citations
55	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European Heart Journal, 2017, 38, ehw480.	2.2	137
56	The fear of dying and occurrence of posttraumatic stress symptoms after an acute coronary syndrome: A prospective observational study. Journal of Health Psychology, 2017, 22, 208-217.	2.3	14
57	Lipoprotein(a): the revenant. European Heart Journal, 2017, 38, 1553-1560.	2.2	133
58	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	3.7	29
59	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. European Heart Journal, 2017, 38, 3493-3502.	2.2	46
60	Early Discharge in Low-Risk Patients Hospitalized for Acute Coronary Syndromes: Feasibility, Safety and Reasons for Prolonged Length of Stay. PLoS ONE, 2016, 11, e0161493.	2.5	13
61	Evidence and controversies regarding the screening for subclinical hypothyroidism in patients with cardiovascular disease. Journal of Thoracic Disease, 2016, 8, E446-E450.	1.4	1
62	Health utility indexes in patients with acute coronary syndromes. Open Heart, 2016, 3, e000419.	2.3	14
63	Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Current Cardiology Reports, 2016, 18, 48.	2.9	4
64	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. Circulation, 2016, 134, 698-709.	1.6	99
65	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. European Journal of Internal Medicine, 2016, 35, 83-88.	2.2	1
66	The peak of blood lactate during the first 24h predicts mortality in acute coronary syndrome patients under extracorporeal membrane oxygenation. International Journal of Cardiology, 2016, 221, 741-745.	1.7	24
67	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre beforeâ€“after study with parallel group comparisons. BMJ Open, 2016, 6, e011520.	1.9	18
68	A Randomized Study of SheathLess vs Standard Guiding Catheters for Transradial Percutaneous Coronary Interventions. Canadian Journal of Cardiology, 2016, 32, 1425-1432.	1.7	16
69	Identifying familial hypercholesterolemia in acute coronary syndrome. Current Opinion in Lipidology, 2016, 27, 375-381.	2.7	18
70	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. European Heart Journal, 2016, 37, 546-553.	2.2	120
71	Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?. European Heart Journal, 2016, 37, 3569-3575.	2.2	30
72	Should we screen for hypothyroidism in patients with cardiovascular disease?. European Heart Journal, 2016, 37, 2066-2068.	2.2	5

#	Article	IF	Citations
73	Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. Atherosclerosis, 2016, 245, 181-186.	0.8	49
74	Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. Swiss Medical Weekly, 2016, 146, w14275.	1.6	2
75	New concepts in the management of dyslipidaemiaa. Swiss Medical Weekly, 2016, 146, w14378.	1.6	0
76	Coronary artery disease is associated with persistent lower quality of life in women. Open Heart, 2015, 2, e000305.	2.3	4
77	Stairs instead of elevators at the workplace decreases <scp>PCSK</scp>9 levels in a healthy population. European Journal of Clinical Investigation, 2015, 45, 1017-1024.	3.4	34
78	Low statin use in adults hospitalized with acute coronary syndrome. Preventive Medicine, 2015, 77, 131-136.	3.4	18
79	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. European Journal of Internal Medicine, 2015, 26, 56-62.	2.2	37
80	Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis, 2015, 239, 118-124.	0.8	26
81	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal, 2015, 36, 2438-2445.	2.2	129
82	Sweetless'n low LDL-C targets for PCSK9 treatment : FigureÂ1. European Heart Journal, 2015, 36, 1146-1148.	2.2	10
83	PCSK9 inhibitors. Swiss Medical Weekly, 2015, 145, w14094.	1.6	13
84	Use and role of monoclonal antibodies and other biologics in preventive cardiology. Swiss Medical Weekly, 2015, 145, w14179.	1.6	3
85	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. PLoS ONE, 2014, 9, e93147.	2.5	28
86	Association of electrocardiogram abnormalities and incident heart failure events. American Heart Journal, 2014, 167, 869-875.e3.	2.7	14
87	Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2013, 13, 4-12.	1.2	56
88	Subclinical Thyroid Dysfunction and the Risk of Heart Failure Events. Circulation, 2012, 126, 1040-1049.	1.6	410
89	Ruling out coronary heart disease in primary care patients with chest pain: a clinical prediction score. BMC Medicine, 2010, 8, 9.	5.5	33